Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTX-030 + chemotherapy ± budigalimab vs chemotherapy in first-line metastatic pancreatic adenocarcinoma
2023-508356-19-00Phase 2Completed
- Sponsor
- Trishula Therapeutics
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of eztilimab and budigalimab in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Trishula Therapeutics. Primary endpoint: Progression-free survival. Started May 2024; status: completed.
02
Drugs
eztilimabbudigalimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-508356-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508356-19-00.